Compare OLP & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OLP | ADCT |
|---|---|---|
| Founded | 1982 | 2011 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 478.2M | 496.7M |
| IPO Year | N/A | 2020 |
| Metric | OLP | ADCT |
|---|---|---|
| Price | $21.31 | $3.88 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $7.60 |
| AVG Volume (30 Days) | 138.0K | ★ 1.7M |
| Earning Date | 11-06-2025 | 11-10-2025 |
| Dividend Yield | ★ 8.38% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.54 | N/A |
| Revenue | ★ $97,423,000.00 | $75,209,000.00 |
| Revenue This Year | $7.95 | $10.36 |
| Revenue Next Year | $6.06 | $3.87 |
| P/E Ratio | $13.96 | ★ N/A |
| Revenue Growth | ★ 9.29 | 6.35 |
| 52 Week Low | $19.62 | $1.05 |
| 52 Week High | $29.23 | $4.80 |
| Indicator | OLP | ADCT |
|---|---|---|
| Relative Strength Index (RSI) | 62.54 | 47.51 |
| Support Level | $20.90 | $3.15 |
| Resistance Level | $21.25 | $4.28 |
| Average True Range (ATR) | 0.34 | 0.42 |
| MACD | 0.10 | -0.00 |
| Stochastic Oscillator | 84.39 | 54.46 |
One Liberty Properties Inc is a self-administered and self-managed real estate investment trust. It acquires, owns, and manages a geographically diversified portfolio consisting mainly of industrial and, to a lesser extent, retail properties, many of which are subject to long-term net leases. The trust has approximately one hundred two properties located across several states in the United States of America. A majority of its revenue is generated in the form of rental income.
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).